NCT05589896 is a Phase 1, PHASE2 clinical trial of Ossium HPC Marrow, Bone Marrow Transplant in Acute Leukemia, sponsored by Ossium Health, Inc..

Who is sponsoring NCT05589896?

NCT05589896 is sponsored by Ossium Health, Inc..

What drugs are being tested in NCT05589896?

Interventions in NCT05589896: Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC), Post-transplant treatment.

What condition does NCT05589896 study?

NCT05589896 studies Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia, Acute Undifferentiated Leukemia, CLL (Chronic Lymphocytic Leukemia), Chronic Myeloid Leukemia (CML), MDS (Myelodysplastic Syndrome), Non-Hodgkin Lymphomas, Hodgkins Lymphoma, Cutaneous T Cell Lymphomas (CTCL).

Is NCT05589896 still recruiting?

NCT05589896 is currently recruiting now. Last updated 24 February 2026.

Last reviewed 2026-02-24 · How we verify

NCT05589896

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Recruiting now Phase 1, PHASE2 Last updated 24 February 2026

What this trial tests

Phase 1, PHASE2 trial testing Ossium HPC Marrow, Bone Marrow Transplant in Acute Leukemia in 12 participants. Currently enrolling.

Timeline

16 August 2024

Primary endpoint
31 May 2026

31 March 2027

Quick facts

Lead sponsor	Ossium Health, Inc.
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	16 August 2024
Primary completion	31 May 2026
Estimated completion	31 March 2027
Sites	9 locations across United States

Drugs / interventions tested

Ossium HPC Marrow, Bone Marrow Transplant
Pre-transplant conditioning - Myeloablative (MAC)
Pre-transplant conditioning - Reduced Intensity (RIC)
Post-transplant treatment

Conditions studied

Acute Leukemia — all drugs for Acute Leukemia →
Acute Lymphoblastic Leukemia — all drugs for Acute Lymphoblastic Leukemia →
Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
Acute Biphenotypic Leukemia — all drugs for Acute Biphenotypic Leukemia →

Sponsor

Ossium Health, Inc. — full company profile →

Who can join

Adults 18 to 75, any sex, with Acute Leukemia or Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute and chronic leukemias, myelodysplastic syndrome, and certain lymphomas. Patients will either receive myeloablative conditioning or reduced intensity conditioning regimen prior to the transplant. Patients will be followed for 56 days for safety endpoints and remain in follow-up for one year.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Successful engraftment in myeloablative transplant with cadaveric bone marrow after sudden unavailability of living donor.
Vasu S, Wall S, Larkin K, Munjal S, et al · · 2026 · PMID 41259738 · DOI 10.1182/bloodadvances.2025018888

Verify or expand the search:

Other recruiting trials for Acute Leukemia

Currently open trials in the same condition.

NCT07270770 — BY002 IIT Study in R/R Acute Leukemia · Phase 1 · recruiting
NCT07356154 — A Study of Revumenib and Mezigdomide in People With Leukemia · Phase 1, PHASE2 · recruiting
NCT07362095 — Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) · Phase 1, PHASE2 · recruiting
NCT07101497 — Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia · Phase 2 · recruiting
NCT06984536 — Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT · Phase 2 · recruiting

Other Ossium Health, Inc. trials

Trials by the same sponsor.

NCT05443464 — Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD) · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05589896 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ossium Health, Inc.
Last refreshed: 24 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05589896.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing